2021
DOI: 10.3390/vaccines9070727
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Applications and Immunological Aspects of Electroporation-Based Therapies

Abstract: Reversible electropermeabilization (RE) is an ultrastructural phenomenon that transiently increases the permeability of the cell membrane upon application of electrical pulses. The technique was described in 1972 by Neumann and Rosenheck and is currently used in a variety of applications, from medicine to food processing. In oncology, RE is applied for the intracellular transport of chemotherapeutic drugs as well as the delivery of genetic material in gene therapies and vaccinations. This review summarizes the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 12 publications
(1 citation statement)
references
References 181 publications
(279 reference statements)
0
1
0
Order By: Relevance
“…As such, we remind that each PEF-based approach has been described in more detail elsewhere [14,78,214,[263][264][265], and systematic reviews on their efficacy are also available [78,80,83,152,162,177,188,210,214,255]. Now, the current challenges pertain to refining treatment indications, individuating the most advantageous timing of treatment application, modulation of treatment intensity (e.g., pulse parameters, number of applications, drug doses, treatment frequency), selection of the target lesions (e.g., primary tumour or distant metastases), and development of combined strategies with local therapies or systemic treatment such as checkpoint inhibitors [248,266]. These issues represent a matter of debate at MDT meetings, where the treatment decision-making still lacks essential information.…”
Section: Discussionmentioning
confidence: 99%
“…As such, we remind that each PEF-based approach has been described in more detail elsewhere [14,78,214,[263][264][265], and systematic reviews on their efficacy are also available [78,80,83,152,162,177,188,210,214,255]. Now, the current challenges pertain to refining treatment indications, individuating the most advantageous timing of treatment application, modulation of treatment intensity (e.g., pulse parameters, number of applications, drug doses, treatment frequency), selection of the target lesions (e.g., primary tumour or distant metastases), and development of combined strategies with local therapies or systemic treatment such as checkpoint inhibitors [248,266]. These issues represent a matter of debate at MDT meetings, where the treatment decision-making still lacks essential information.…”
Section: Discussionmentioning
confidence: 99%